Department of Psychiatry, Arak University of Medical Sciences, Arak, Iran; Traditional and Complementary Medicine Research Center, Arak University of Medical Sciences, Arak, Iran.
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Aug 30;94:109651. doi: 10.1016/j.pnpbp.2019.109651. Epub 2019 May 13.
In the current meta-analysis of randomized controlled trials (RCTs), the effects of vitamin D supplementation on mental health, and biomarkers of inflammation and oxidative stress in patients with psychiatric disorders are assessed.
The following databases were search up to March 2019: MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials. The quality of the relevant extracted data was assessed according to the Cochrane risk of bias tool. Data were pooled by the use of the inverse variance method and expressed as mean difference with 95% Confidence Intervals (95% CI).
Eleven effect sizes from nine studies were included in the final analyses. A pooled analysis of 9 effect sizes showed a significant reduction in Beck Depression Inventory (BDI) score following supplementation with vitamin D [weighted mean difference (WMD): -3.91; 95% CI: -5.15 -2.66), I= 85.9%]. Combining data from two available studies on the effects of vitamin D supplementation on Pittsburgh Sleep Quality Index (PSQI) also revealed a significant reduction in this score following the intervention (WMD: -1.78; 95% CI: -2.28, -1.28). In addition, there were significant increase in glutathione (GSH) through 3 studies (WMD: 180.70; 95% CI: 6.76, 354.64), and in total antioxidant capacity (TAC) through 3 studies (WMD: 90.09; 95% CI: 56.36, 123.82) after vitamin D supplementation. Combining data from five studies, we found a significant reduction in C-reactive protein (CRP) concentrations after vitamin D supplementation (WMD: -1.74; 95% CI: -2.82, -0.66).
Overall, the current meta-analysis demonstrated that taking vitamin D supplements among patients with psychiatric disorders had beneficial effects on BDI, PSQI, GSH, TAC and CRP levels, but did not affect other biomarkers of inflammation and oxidative stress.
在当前对随机对照试验（RCT）的荟萃分析中，评估了维生素 D 补充对精神疾病患者心理健康以及炎症和氧化应激生物标志物的影响。
截至 2019 年 3 月，我们检索了以下数据库：MEDLINE、EMBASE、Web of Science 和 Cochrane 对照试验中心注册库。根据 Cochrane 偏倚风险工具评估了相关提取数据的质量。使用逆方差法汇总数据，并以均数差值（MD）和 95%置信区间（95%CI）表示。
最终分析纳入了 9 项研究的 11 个效应量。对 9 个效应量的汇总分析显示，维生素 D 补充后贝克抑郁量表（BDI）评分显著降低[加权均数差值（WMD）：-3.91；95%CI：-5.15 至-2.66），I=85.9%]。结合两项关于维生素 D 补充对匹兹堡睡眠质量指数（PSQI）影响的研究数据，干预后 PSQI 评分也显著降低（WMD：-1.78；95%CI：-2.28 至-1.28）。此外，通过 3 项研究发现谷胱甘肽（GSH）显著增加（WMD：180.70；95%CI：6.76 至 354.64），通过 3 项研究发现总抗氧化能力（TAC）显著增加（WMD：90.09；95%CI：56.36 至 123.82）。综合 5 项研究的数据，我们发现维生素 D 补充后 C 反应蛋白（CRP）浓度显著降低（WMD：-1.74；95%CI：-2.82 至-0.66）。
总体而言，当前的荟萃分析表明，精神疾病患者补充维生素 D 对 BDI、PSQI、GSH、TAC 和 CRP 水平有有益影响，但对其他炎症和氧化应激生物标志物没有影响。
